background
extent
spread
sar
coronaviru
uk
elsewher
unknown
typic
symptomat
individu
diagnos
perform
serolog
studi
recent
blood
donor
scotland
detect
antibodi
ccbi
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
marker
past
infect
interpret
although
use
rise
number
seroposit
infer
contemporari
seropreval
growth
rate
epidem
note
consist
frequenc
report
diagnos
infect
death
report
time
period
scotland
given
seroconvers
take
week
also
note
blood
donor
repres
gener
popul
particular
histori
recent
respiratori
infect
defer
sinc
first
report
decemb
infect
report
increas
number
countri
worldwid
particularli
high
incid
diagnos
infect
associ
death
respiratori
diseas
initi
china
recent
itali
iran
spain
franc
usa
http
increas
age
male
gender
smoke
comorbid
cardiac
diseas
hypertens
diabet
identifi
risk
factor
sever
infect
yet
unknown
reason
infant
children
seem
less
risk
moder
sever
diseas
compar
itali
spain
pandem
rel
earli
stage
uk
earli
march
howev
dramat
rise
number
admiss
patient
sever
infect
follow
emerg
plan
implement
predict
futur
sever
outbreak
specif
trajectori
sever
case
requir
hospitalis
intens
care
support
key
nation
respons
throughout
sever
affect
countri
worldwid
predict
diseas
outcom
complex
addit
basic
inform
proport
individu
differ
age
rang
develop
sever
diseas
sever
outbreak
also
crucial
depend
current
popul
immun
viru
transmiss
mean
estim
interquartil
rang
studi
base
presum
naiv
popul
indic
minimum
level
herd
immun
past
infect
suffici
sustain
reduct
new
infect
time
spread
may
influenc
season
chang
transmiss
observ
respiratori
coronavirus
infect
human
current
studi
taken
first
step
toward
estim
exposur
european
countri
measur
seropreval
sampl
blood
donat
sampl
donor
age
rang
year
collect
across
scotland
th
march
st
rd
march
assay
neutralis
antibodi
use
pseudotyp
viru
microneutralis
pmn
assay
format
use
previous
ebolaviru
seroepidemiolog
purpos
confirm
use
ccbi
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
ccbi
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
assay
plate
barcod
control
space
throughout
run
individu
blind
regard
arrang
space
posit
control
plate
enzymelink
immunosorb
assay
elisa
antibodi
trimer
protein
detect
elisa
maxisorp
immunopl
nunc
coat
strepmabclass
iba
plate
block
skim
milk
pb
one
hour
incub
solubl
trimer
trimer
spike
protein
skim
milk
pb
one
hour
plasma
ad
dilut
follow
alpconjug
antihuman
igg
sigma
dilut
alpconjug
antihuman
igm
sigma
dilut
reaction
develop
addit
pnpp
substrat
stop
naoh
absorb
measur
hour
statist
model
analysi
sampl
analys
follow
protocol
outlin
ferrara
temperton
implement
use
scipi
curv
fit
valu
plate
correct
background
signal
subtract
averag
neg
control
well
standardis
percentag
neutralis
sampl
valu
calcul
benchmark
averag
technic
posit
control
plate
use
equat
standardis
percentag
two
replic
sampl
averag
dilut
threeparamet
logist
function
fit
averag
use
nonlinear
least
squar
ccbi
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
http
doi
medrxiv
preprint
averag
standardis
neutralis
percentag
function
logarithm
base
dilut
factor
inhibitori
concentr
valu
correspond
dilut
factor
neutralis
predict
achiev
larger
valu
correspond
sampl
stronger
antibodi
respons
requir
higher
dilut
reduc
neutralis
paramet
describ
asymptot
curv
fix
neutralis
maximum
paramet
describ
steep
slope
sigmoid
curv
restrict
take
valu
neg
respons
neutralis
dose
permit
qualiti
inver
health
board
area
approxim
equal
represent
male
femal
amongst
donor
restrict
age
rang
minimum
donor
age
fig
also
skew
toward
older
age
rang
compar
scottish
popul
within
rang
fig
suppl
data
sampl
week
control
assay
pmn
assay
use
twofold
dilut
seri
plasma
reduct
luciferas
signal
ccbi
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
http
doi
medrxiv
preprint
antibodi
bind
dilut
curvefit
order
estim
dilut
lead
inhibit
pseudotyp
replic
second
metric
degre
fit
datapoint
dilut
seri
predict
sigmoid
curv
use
fit
express
r
sampl
show
nonspecif
block
entri
ie
nonconcentr
depend
show
low
r
valu
posit
control
sampl
possess
detect
neutralis
abil
rang
seen
prepandem
sampl
good
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
http
doi
medrxiv
preprint
scotland
time
sampl
collect
interpret
signific
seropreval
review
sever
factor
may
influenc
antibodi
detect
rate
might
translat
calcul
popul
exposur
immun
project
outcom
outbreak
repres
studi
region
studi
base
upon
test
anonymis
sampl
blood
donor
collect
march
scotland
popul
million
rel
low
popul
densiti
howev
contain
sever
larg
citi
glasgow
edinburgh
geospati
would
support
transmiss
network
typic
much
western
europ
public
health
data
case
indic
th
march
shortli
donor
collect
total
infect
diagnos
death
record
normalis
incid
compar
overal
confirm
incid
uk
day
rate
scotland
higher
germani
compar
denmark
franc
spain
substanti
lower
itali
valu
comparison
temper
potenti
differ
countri
criteria
use
attribut
death
infect
furthermor
situat
highli
dynamicon
st
april
rate
scotland
risen
much
higher
england
rate
may
diverg
futur
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
http
doi
medrxiv
preprint
comprehens
analysi
publish
china
cdc
estim
infect
mild
inappar
diseas
symptom
upper
respiratori
tract
viral
infect
mild
fever
cough
dri
sore
throat
nasal
congest
malais
headach
muscl
pain
without
dyspnoea
sign
respiratori
distress
insuffici
given
symptom
differ
substanti
winter
respiratori
infect
like
substanti
proport
estim
mild
case
would
proceed
donat
sensit
specif
serolog
test
use
current
agre
standard
control
avail
serolog
test
result
present
studi
therefor
base
formal
nonvalid
assay
howev
believ
neutralis
antibodi
test
like
robust
firstli
base
design
pmn
assay
ebolaviru
influenza
viru
pmn
assay
demonstr
high
specif
target
viru
neutralis
antibodi
sensit
often
greater
achiev
neutralis
antibodi
assay
whole
viru
overal
although
sampl
limit
concord
pmn
assay
detect
neutralis
antibodi
detect
antispik
igg
antibodi
elisa
pmn
assay
howev
requir
comparison
neutralis
live
viru
interpret
data
specif
assay
potenti
influenc
crossreact
human
coronavirus
includ
respiratori
virus
hkui
betacoronaviru
genu
circul
winter
month
previou
studi
indic
absenc
reactiv
neg
control
sera
spike
protein
elisa
high
specif
assay
base
spike
protein
compar
use
conserv
nucleoprotein
whole
viru
spike
protein
like
share
specif
exist
data
neutralis
antibodi
indic
assay
specif
may
even
greater
although
enter
cell
receptor
possess
structur
similar
spike
protein
recent
demonstr
neutralis
monoclon
antibodi
mab
infect
bound
neutralis
convers
mab
rais
show
littl
crossneutralis
howev
crossreact
unlik
caus
assay
specif
problem
never
spread
significantli
uk
elsewher
europ
ccbi
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
http
doi
medrxiv
preprint
serolog
test
use
determin
popul
exposur
base
upon
assumpt
durabl
virusspecif
igg
antibodi
respons
infect
persist
year
infect
typic
assum
seropreval
studi
mani
human
pathogen
includ
polioviru
measl
hepat
b
viru
littl
inform
howev
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
http
doi
medrxiv
preprint
gener
antibodi
detect
commerci
elisa
test
technic
consider
asid
tempor
gap
exposur
seroconvers
coupl
rapid
spread
viru
mean
initi
phase
epidem
import
differ
exist
given
time
point
fraction
recent
exposedinfect
fraction
seroconvert
ccbi
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
ccbi
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
number
seroposit
blood
donor
sampl
studi
divid
region
health
board
sampl
densiti
indic
shade
region
locat
seroposit
donor
indic
red
text
arrow
border
histogram
show
sampl
frequenc
differ
age
class
week
blue
week
grey
health
board
ccbi
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
postpandem
posit
elisa
test
sampl
indic
fill
red
squar
dot
line
indic
highest
valu
found
among
prepandem
sampl
ccbi
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
ccbi
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
